|
|
Volumn 295, Issue 5563, 2002, Pages 2198-2199
|
|
Cancer therapy: Setbacks for endostatin
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
TUMORS;
CLINICAL TRIALS;
ONCOLOGY;
ENDOSTATIN;
CANCER;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ANGIOGENESIS;
CANCER RESEARCH;
DRUG EFFECT;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG POTENCY;
DRUG RESEARCH;
DRUG TARGETING;
GENE EXPRESSION;
GENE THERAPY;
GENE TRANSFER;
HEMATOPOIETIC STEM CELL;
NONHUMAN;
OSMOTIC PUMP;
PRIORITY JOURNAL;
SHORT SURVEY;
TUMOR REGRESSION;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTINEOPLASTIC AGENTS;
COLLAGEN;
ENDOSTATINS;
FIBROSARCOMA;
GENE THERAPY;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, ACUTE;
MICE;
PEPTIDE FRAGMENTS;
REPRODUCIBILITY OF RESULTS;
|
|
EID: 0037155610
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.295.5563.2198 Document Type: Short Survey |
|
Times cited : (59)
|
|
References (0)
|